Literature DB >> 15767912

[Prevalence and prenatal diagnosis of congenital malformations in the Parisian population: twenty years of surveillance by the Paris Registry of congenital malformations].

C De Vigan1, B Khoshnood, A Lhomme, V Vodovar, J Goujard, F Goffinet.   

Abstract

OBJECTIVES: To assess overall and malformation-specific trends in the prevalence, prenatal diagnosis and pregnancy termination of congenital malformations in the Parisian population.
METHODS: We used data from the Paris Registry of Congenital Malformations, which includes all births and pregnancy terminations with structural birth defects or chromosomal anomalies. Data on total and live birth prevalence were available for the period 1981-2000 and for prenatal diagnosis and pregnancy terminations for 1983-2000. Twenty malformations were selected for malformation-specific analyses due to their higher frequency and consistent definitions in different classification systems.
RESULTS: For the period 1981-2000, the overall total prevalence of malformations was 3.2%. Prenatal diagnosis rates consistently increased from 16.2% (95% CI, 13.8-18.6) of cases with malformation in 1983 to 69.1% (95% CI, 66.7-71.5) in 2000. Pregnancy terminations increased from 8.8% (95% CI, 7.0-10.8) of cases with malformation in 1983 to 30.1% (95% CI, 27.7-32.6) in 2000.
CONCLUSION: Registries of congenital malformations provide population-based data on the prevalence of malformations and their associations with other anomalies. Registry-based data can also be used to evaluate the impact of prenatal testing policies for congenital malformations.

Entities:  

Mesh:

Year:  2005        PMID: 15767912     DOI: 10.1016/s0368-2315(05)82665-1

Source DB:  PubMed          Journal:  J Gynecol Obstet Biol Reprod (Paris)        ISSN: 0150-9918


  7 in total

1.  Antenatal imaging: does the postnatal impact justify the effort?

Authors:  Laurent Garel
Journal:  Pediatr Radiol       Date:  2011-01-13

2.  Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study.

Authors:  Isabelle Lacroix; Alain Berrebi; Daniel Garipuy; Laurent Schmitt; Yamina Hammou; Catherine Chaumerliac; Maryse Lapeyre-Mestre; Jean-Louis Montastruc; Christine Damase-Michel
Journal:  Eur J Clin Pharmacol       Date:  2011-05-03       Impact factor: 2.953

3.  IBD: measuring what counts-safety of IBD medications in pregnancy.

Authors:  Barrett G Levesque; Sunanda V Kane
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02-08       Impact factor: 46.802

4.  Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database.

Authors:  I Lacroix; C Hurault; M F Sarramon; C Guitard; A Berrebi; M Grau; C Albouy-Cossard; R Bourrel; E Elefant; J L Montastruc; C Damase-Michel
Journal:  Eur J Clin Pharmacol       Date:  2009-04-14       Impact factor: 2.953

5.  Prevalence of esophageal atresia among 18 international birth defects surveillance programs.

Authors:  Natasha Nassar; Emanuele Leoncini; Emmanuelle Amar; Jazmín Arteaga-Vázquez; Marian K Bakker; Carol Bower; Mark A Canfield; Eduardo E Castilla; Guido Cocchi; Adolfo Correa; Melinda Csáky-Szunyogh; Marcia L Feldkamp; Babak Khoshnood; Danielle Landau; Nathalie Lelong; Jorge S López-Camelo; R Brian Lowry; Robert McDonnell; Paul Merlob; Julia Métneki; Margery Morgan; Osvaldo M Mutchinick; Miland N Palmer; Anke Rissmann; Csaba Siffel; Antonin Sìpek; Elena Szabova; David Tucker; Pierpaolo Mastroiacovo
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2012-09-03

6.  Incidence of neural tube defects and their risk factors within a cohort of Moroccan newborn infants.

Authors:  Khenata Forci; El Arbi Bouaiti; Mohamed Hassan Alami; Asmaa Mdaghri Alaoui; Amal Thimou Izgua
Journal:  BMC Pediatr       Date:  2021-03-15       Impact factor: 2.125

7.  Reproductive health and pregnancy outcomes among French gulf war veterans.

Authors:  Catherine Verret; Mathe-Aline Jutand; Catherine De Vigan; Marion Bégassat; Lynda Bensefa-Colas; Patrick Brochard; Roger Salamon
Journal:  BMC Public Health       Date:  2008-04-28       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.